Early detection of small tumors by non-invasive imaging holds the potential to substantially improve cancer patient survival and improve quality of life. However, early detection is currently limited to detecting masses composed of more than about one billion tumor cells. Improving upon this billion-cell threshold will require methods to deliver molecular imaging agents to tumors with increased selectivity, and to avoid the uptake of imaging agents in normal tissues. To reduce background and improve imaging contrast, a molecular imaging agent is proposed wherein tumor uptake will be amplified by the action of enzymes known to be selectively active in tumors. To accomplish this, we will first identify and affinity matures an antibody fragment with high affinity and specificity for a receptor present in breast tumors and other tumor types. The antibody will then be modified using protein engineering methods render binding activity dependent upon protease activity thereby generating protease- activated antibodies. In parallel, we will use protein display technologies to identify protease substrates that exhibit the requisite properties of activity, selectivity, and stability to enable precise in vivo targeting. Protease-activated antibody imaging probes will be designed to exhibit cross reactivity between human and mouse tumor receptor homologs to allow for the possibility of rapid translation to the clinic. The increase in selectivity and resultant increase in imaging contrast conferred by protease-activated antibodies will be assessed in mouse xenograft models by near-infrared imaging. This work is expected to yield highly-targeted, protease-activity imaging probes that exhibit increased selectivity for detecting multiple tumor types, and that could enable earlier tumor detection, or tumor phenotyping. More generally, this project will demonstrate a novel methodological approach that could be broadly applied to improve contrast in a variety of imaging applications. )

Public Health Relevance

Despite improvement in cancer therapeutics, early tumor detection and removal remains one of the most effective treatment strategies and holds potential to further reduce the incidence of life-threatening cancer. This work aims to design and build a new family of biomolecules that can sense and respond to the tumor, enabling earlier detection of very small tumors and treatment or surgical removal to increase patient survival. )

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA159232-02
Application #
8333951
Study Section
Clinical Molecular Imaging and Probe Development (CMIP)
Program Officer
Menkens, Anne E
Project Start
2011-09-16
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2014-08-31
Support Year
2
Fiscal Year
2012
Total Cost
$158,369
Indirect Cost
$49,619
Name
University of California Santa Barbara
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
094878394
City
Santa Barbara
State
CA
Country
United States
Zip Code
93106